Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Filming

Nature custom video - How to beat a brain-eating amoeba

A decade-long fight against a brain-eating amoeba

Our Nature Custom Media team recently took on an ambitious project: producing a video that spanned two continents, covered a decade of medical progress, and navigated regulatory hurdles.

Springer Nature

- PMLiVE

AstraZeneca shares late-stage results for Airsupra in mild asthma patients

More than ten million asthma exacerbations occur in the US every year

- PMLiVE

AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

Up to 262 million people worldwide are affected by the chronic respiratory disease

- PMLiVE

Chiesi report highlights incorrect inhaler use among UK asthma patients

The long-term lung condition affects around 7.2 million people in the UK

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

UK researchers uncover first new asthma and COPD attack treatment in 50 years

The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

- PMLiVE

AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

The chronic respiratory disease is estimated to affect up to 262 million people globally

- PMLiVE

GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition

The deal includes a monoclonal antibody ready to enter phase 2 development for asthma

Top 10 benefits of virtual advisory boards: Increased Engagement and Insights

#2. Increased Advisor Engagement and Quality and Quantity of Insights

Impetus Digital

- PMLiVE

AstraZeneca’s mild combination asthma reliever approved in UK

Over two and a half million adults with mild cases of asthma could be eligible for the treatment

- PMLiVE

AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval

Airsupra significantly reduces the risk of severe asthma exacerbations

- PMLiVE

AZ and Avillion’s asthma rescue treatment recommended by FDA Advisory Committee

PT027 significantly reduced the risk of severe asthma exacerbations

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links